ReviewOncogene2026
The role of Rho-associated coiled-coil kinases (ROCK) in cancer.
Review in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rho-associated coiled-coil kinases (ROCKs) regulate the actin cytoskeleton by controlling cellular functions such as cell contraction, migration and adhesion. Within the ROCK family, two highly homologous isoforms with overlapping functions exist: ROCK1 and ROCK2. The roles of ROCKs are context-dependent, varying by cell type and microenvironment and have been associated with a variety of diseases, including cancer. Increasing evidence correlates ROCK overexpression with cancer progression, metastasis and therapeutic resistance, while ROCK2 inhibition has demonstrated greater tumour inhibition. By regulating cytoskeletal dynamics and phosphorylating downstream effectors, the RhoA/ROCK2 signalling pathway orchestrates cellular processes including cytoskeletal reorganisation, cellular motility and mediating cell cycle progression with specific roles in the epithelial-mesenchymal transition (EMT), vascular mimicry (VM) and fibrosis. Crosstalk with neighbouring pathways further amplifies these oncogenic effects, but our understanding remains incomplete. This review discusses the role of Rho-associated coiled-coil kinases, ROCK2 in particular, in carcinogenesis.
Indexed as
Identifiers
41933134What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.